Fexinidazole

From WikiMD's Wellness Encyclopedia

What is Fexinidazole?[edit | edit source]

Fexinidazole
Error creating thumbnail:
Fexinidazole Structural Formula V1
Error creating thumbnail:
Trypanosoma brucei gambiense - trypomastigote
SymptomsAfricanTrypanosomiasis



What are the uses of this medicine?[edit | edit source]

  • Fexinidazole Tablets are used for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

Limitations of Use:

  • Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/µL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options.


How does this medicine work?[edit | edit source]

  • Fexinidazole is an antiprotozoal drug.
  • Studies with Trypanosoma brucei and other protozoans suggest that, like for other nitro-containing drugs, the nitroreductase (NTR) enzyme plays an important role in the bioactivation of fexinidazole resulting in generation of reactive amines and damage to DNA and proteins.
  • The activity of fexinidazole and its metabolites (M1 and M2) is trypanocidal and appears to be concentration and time dependent.
  • Fexinidazole and its two metabolites, M1 and M2, are active against the trypanosomes of Trypanosoma brucei gambiense.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients with:


What drug interactions can this medicine cause?[edit | edit source]


Is this medicine FDA approved?[edit | edit source]

  • Fexinidazole was approved for medical use in the United States in July 2021.


How should this medicine be used?[edit | edit source]

Recommended dosage:

  • Recommended Dosage of Fexinidazole Tablets in Patients 6 years of age and older and weighing at least 20 kg as below:
Body Weight Type of Dose Daily Dose Number of Tablets Duration of Treatment
Greater than or equal to 35 kg Loading dose 1,800 mg 3 4 days
Greater than or equal to 20 kg to less than 35 kg Loading dose 1,200 mg 2 4 days

Administration:

  • Administer Fexinidazole Tablets, orally, once daily for a total of 10 days (loading dose plus maintenance dose) with food each day at about the same time of the day.
  • Do not break or crush Fexinidazole Tablets.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Tablets: 600 mg

This medicine is available in fallowing brand namesː

  • FEXINIDAZOLE tablet


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:


What special precautions should I follow?[edit | edit source]

  • Decreased efficacy was observed in patients treated with Fexinidazole Tablets as compared to nifurtimox-eflornithine combination therapy (NECT)-treated patients. Patients with severe second stage HAT (CSF-WBC >100 cells/µL) due to T. brucei gambiense disease should only be treated with Fexinidazole Tablets if there are no other available treatment options.
  • Prolongation of the QT interval due to Fexinidazole Tablets occurs in a concentration-dependent manner. Avoid use in patients with known prolongation, proarrhythmic conditions, and concomitant use with drugs that prolong the QT interval, those that block cardiac potassium channels, and/or those that induce bradycardia, or are inducers of hepatic CYP450.
  • Adult patients treated with Fexinidazole Tablets reported a higher percentage of Central Nervous System (CNS) and psychiatric-related adverse reactions than those treated with nifurtimox eflornithine combination therapy (NECT). Adverse reactions such as agitation, anxiety, abnormal behavior, depression, suicidal ideation, nightmares, hallucination, and personality change have been observed during therapy. Inform patients and their caregivers of the risk. Consider alternative therapy or increased monitoring of the patient, including hospitalization in patients with psychiatric disorders, or if these adverse reactions occur.
  • Neutropenia (absolute neutrophil count less than 1,000 cells/mm3) has been reported in patients receiving Fexinidazole Tablets. Avoid concomitant use of drugs which may cause neutropenia and monitor leukocyte count periodically. Monitor patients with neutropenia for symptoms or signs of infection.
  • Elevations in liver transaminases occurred in less than two percent of patients receiving Fexinidazole Tablets for the treatment of HAT. Evaluate liver-related laboratory tests at the start and during treatment.
  • Nitroimidazole-class drugs may cause a disulfiram-like reaction in patients who concurrently consume alcohol. Advise patients to avoid consumption of alcohol during treatment with and for at least 48 hours after completing therapy.
  • Psychotic reactions have been reported in patients concurrently taking disulfiram and nitroimidazole-class drugs. Avoid use in patients who have taken disulfiram within the last two weeks.
  • Advise the patient that Fexinidazole Tablets must be taken with food each day at about the same time of the day (e.g., during or immediately after the main meal of the day), to make sure it is adequately absorbed.
  • Counsel the patient that they should not drive or use machines if they feel tired or dizzy. Dizziness, fatigue, asthenia, and somnolence have been reported following treatment with Fexinidazole Tablets.


What to do in case of emergency/overdose?[edit | edit source]

Symptoms of overdosage may include:

Management of overdosage:

  • There is no specific antidote for Fexinidazole Tablets.
  • Treatment should be supportive with appropriate monitoring.


Can this medicine be used in pregnancy?[edit | edit source]

  • There are risks to the mother and fetus associated with untreated HAT due to T. brucei gambiense during pregnancy.
  • Available data from clinical trials with fexinidazole use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects or miscarriage.


Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of Fexinidazole Tablets for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) HAT due to Trypanosoma brucei gambiense have been established in pediatric patients aged 6 years and older and weighing at least 20 kg.
  • The safety and efficacy of Fexinidazole Tablets have not been established in pediatric patients younger than 6 years old and/or less than 20 kg in body weight.


What are the active and inactive ingredients in this medicine?[edit | edit source]

Active Ingredient:

  • FEXINIDAZOLE

Inactive Ingredients:

  • CROSCARMELLOSE SODIUM
  • LACTOSE MONOHYDRATE
  • MAGNESIUM STEARATE
  • MICROCRYSTALLINE CELLULOSE
  • POVIDONE, UNSPECIFIED
  • SODIUM LAURYL SULFATE


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured by:


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store below 30°C (86°F).
  • Store in the original package in order to protect from light and moisture.


Fexinidazole Resources

Contributors: Deepika vegiraju